The Blood-Brain Barrier in Alzheimer’s Disease

Steffen E. Storck, Anika M.S. Hartz, Claus U. Pietrzik

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

7 Scopus citations


The accumulation of neurotoxic amyloid-beta (Aβ) in the brain is one of the characteristic hallmarks of Alzheimer’s disease (AD). Aβ-peptide brain homeostasis is governed by its production and various clearance mechanisms. The blood-brain barrier provides a large surface area for influx and efflux mechanisms into and out of the brain. Different transporters and receptors have been implicated to play crucial roles in Aβ clearance from brain. Besides Aβ transport, the blood-brain barrier tightly regulates the brain’s microenvironment; however, vascular alterations have been shown in patients with AD. Here, we summarize how the blood-brain barrier changes during aging and in disease and focus on recent findings of how the ABC transporter P-glycoprotein (ABCB1/P-gp) and the receptor low-density lipoprotein receptor-related protein 1 (LRP1) play a role in Aβ clearance from brain.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
Number of pages20
StatePublished - 2022

Publication series

NameHandbook of Experimental Pharmacology
ISSN (Print)0171-2004
ISSN (Electronic)1865-0325

Bibliographical note

Publisher Copyright:
© 2020, Springer Nature Switzerland AG.


  • Alzheimer’s disease (AD)
  • Amyloid-beta (Aβ)
  • Blood-brain barrier
  • Clearance
  • LRP1
  • Neurovascular unit
  • P-gp/ABCB1

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology, Toxicology and Pharmaceutics (all)


Dive into the research topics of 'The Blood-Brain Barrier in Alzheimer’s Disease'. Together they form a unique fingerprint.

Cite this